HomeAI · summaries
Storia in 3 fonti
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens - Merck & Co (NYSE:MRK)
FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Phase 3 STRIDE-13 Data.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Capvaxive approved for children at high risk for pneumococcal disease
The FDA has expanded the approval of Merck’s 21-valent pneumococcal vaccine to include children at increased risk for pneumococcal disease, the drug maker announced…
- ·
morningstar.com
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2…
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for…
